Parkinson's Disease Therapeutics Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
Report Highlights
Parkinson’s Disease Therapeutics Market - Overview
This report on Parkinson’s disease therapeutics market studies the current as well as future prospects of the market globally. Stakeholders of the market include companies and intermediaries engaged in the manufacturing, commercialization, providing therapeutic drugs for treatment of Parkinson’s disease, as well as new entrants planning to enter the market. The report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments considered in the scope of the study. The section also provides overall information and data analysis of the global Parkinson’s disease therapeutics market with respect to the leading market segments based on drug class, route of administration, distribution channel, and geography.
The global Parkinson’s disease therapeutics market is divided into four segments on the basis of drug class, route of administration, distribution channel, and geography. Based on drug class, the market has been further segmented into Levodopa combination, dopamine agonists, MAO-B Inhibitors, COMT Inhibitors, and others. In terms of route of administration, the market has been classified into oral, transdermal, subcutaneous, intestinal infusion, and others. The Parkinson’s disease therapeutics market has also been studied from the point of distribution channel, based on which the market has been bifurcated into hospital pharmacy, retail pharmacy, and online pharmacy.
Each of the market segments has been extensively analyzed based on market-related factors such as increasing incidence and prevalence of Parkinson’s disease. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast in terms of US$ million for each segment have been provided for the period from 2015 to 2025. The report also provides the compound annual growth rate (CAGR) percentage for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.
The market overview section of the report explores the market dynamics such as drivers, restraints, opportunities, and pipeline drugs that currently have a strong impact on the Parkinson’s disease therapeutics market and is likely to influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different geographies. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors are expected to help market players take strategic decisions to strengthen their positions and enhance their shares in the global Parkinson’s disease therapeutics market.
Geographically, Parkinson’s disease therapeutics market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions have been provided for the period from 2015 to 2025, along with their respective CAGR for the forecast period from 2017 to 2025, considering 2016 as the base year. The report provides market size and forecast for the major countries in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market growth and future opportunities has been provided in the market overview section. It also provides market attractiveness analysis and market share analysis of key players, thus presenting a thorough examination of the overall competitive scenario of the global Parkinson’s disease therapeutics market.
Major players operating in the global Parkinson’s disease therapeutics market are AbbVie Inc., Novartis AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., and UCB Inc, which exhibit the widest geographical outreach. Other prominent players operating in the global market include STADA Arzneimittel AG, GlaxoSmithKline plc, Valeant Pharmaceuticals International, Inc., Merck & Co., Inc., and Impax Laboratories Inc.
The global Parkinson’s disease therapeutics market is segmented as follows:
By Drug Class
Levodopa Combination
Dopamine Agonists
MAO-B Inhibitors
COMT Inhibitors
Others
By Route of Administration
Oral
Transdermal
Subcutaneous
Intestinal Infusion
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Geography
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Rest of Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America (LATAM)
Brazil
Mexico
Rest of LATAM
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
- Table 1 : Global Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
- Table 2 : Global Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
- Table 3 : Global Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
- Table 4 : Global Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Region, 2015–2025
- Table 5 : North America Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Country, 2015–2025
- Table 6 : North America Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
- Table 7 : North America Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
- Table 8 : North America Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
- Table 9 : Europe Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Country, 2015–2025
- Table 10 : Europe Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
- Table 11 : Europe Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
- Table 12 : Europe Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
- Table 13 : Asia Pacific Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Country, 2015–2025
- Table 14 : Asia Pacific Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
- Table 15 : Asia Pacific Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
- Table 16 : Asia Pacific Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
- Table 17 : Latin America Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Country, 2015–2025
- Table 18 : Latin America Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
- Table 19 : Latin America Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
- Table 20 : Latin America Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
- Table 21 : Middle East & Africa Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Country, 2015–2025
- Table 22 : Middle East & Africa Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
- Table 23 : Middle East & Africa Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
- Table 24 : Middle East & Africa Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
- Figure 1 : Global Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, 2015–2025
- Figure 2 : Market Value Share, by Drug Class (2016)
- Figure 3 : Market Value Share, by Route of Administration (2016)
- Figure 4 : Market Value Share, by Distribution Channel (2016)
- Figure 5 : Market Value Share, by Region (2016)
- Figure 6 : Global Parkinson's Disease Therapeutics Market Value Share Analysis (US$ Mn), by Drug Class, 2016 and 2025
- Figure 7 : Global Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2017–2025
- Figure 8 : Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Levodopa Combination, 2015–2025
- Figure 9 : Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Dopamine Agonists, 2015–2025
- Figure 10 : Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Monoamine Oxidase B Inhibitors (MAO-B Inhibitors), 2015–2025
- Figure 11 : Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Catechol-O-methyltransferase (COMT) Inhibitors, 2015–2025
- Figure 12 : Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
- Figure 13 : Global Parkinson's Disease Therapeutics Market Value Share Analysis (US$ Mn), by Route of Administration, 2016 and 2025
- Figure 14 : Global Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017–2025
- Figure 15 : Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oral, 2015–2025
- Figure 16 : Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Transdermal, 2015–2025
- Figure 17 : Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Subcutaneous, 2015–2025
- Figure 18 : Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Intestinal Infusion, 2015–2025
- Figure 19 : Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
- Figure 20 : Global Parkinson's Disease Therapeutics Market Value Share Analysis (US$ Mn), by Distribution Channel, 2016 and 2025
- Figure 21 : Global Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
- Figure 22 : Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacy, 2015–2025
- Figure 23 : Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacy, 2015–2025
- Figure 24 : Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacy, 2015–2025
- Figure 25 : Global Parkinson's Disease Therapeutics Market Value Share Analysis, by Region, 2016 and 2025
- Figure 26 : Global Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Region, 2017–2025
- Figure 27 : North America Parkinson's Disease Therapeutics Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
- Figure 28 : North America Parkinson's Disease Therapeutics Market Value Share Analysis (US$ Mn), by Country , 2016 and 2025
- Figure 29 : North America Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Country, 2017–2025
- Figure 30 : North America Parkinson's Disease Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2025
- Figure 31 : North America Parkinson's Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2016 and 2025
- Figure 32 : North America Parkinson's Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2016 and 2025
- Figure 33 : North America Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Drug Class
- Figure 34 : North America Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Route of Administration
- Figure 35 : North America Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel
- Figure 36 : Europe Parkinson's Disease Therapeutics Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
- Figure 37 : Europe Parkinson's Disease Therapeutics Market Value Share Analysis (US$ Mn), by Country, 2016 and 2025
- Figure 38 : Europe Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Country, 2017–2025
- Figure 39 : Europe Parkinson's Disease Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2025
- Figure 40 : Europe Parkinson's Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2016 and 2025
- Figure 41 : Europe Parkinson's Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2016 and 2025
- Figure 42 : Europe Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Drug Class
- Figure 43 : Europe Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Route of Administration
- Figure 44 : Europe Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel
- Figure 45 : Asia Pacific Parkinson's Disease Therapeutics Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
- Figure 46 : Asia Pacific Parkinson's Disease Therapeutics Market Value Share Analysis (US$ Mn), by Country, 2016 and 2025
- Figure 47 : Asia Pacific Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Country, 2017–2025
- Figure 48 : Asia Pacific Parkinson's Disease Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2025
- Figure 49 : Asia Pacific Parkinson's Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2016 and 2025
- Figure 50 : Asia Pacific Parkinson's Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2016 and 2025
- Figure 51 : Asia Pacific Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Drug Class
- Figure 52 : Asia Pacific Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Route of Administration
- Figure 53 : Asia Pacific Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel
- Figure 54 : Latin America Parkinson's Disease Therapeutics Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
- Figure 55 : Latin America Parkinson's Disease Therapeutics Market Value Share Analysis (US$ Mn), by Country, 2016 and 2025
- Figure 56 : Latin America Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Country, 2017–2025
- Figure 57 : Latin America Parkinson's Disease Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2025
- Figure 58 : Latin America Parkinson's Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2016 and 2025
- Figure 59 : Latin America Parkinson's Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2016 and 2025
- Figure 60 : Latin America Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Drug Class
- Figure 61 : Latin America Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Route of Administration
- Figure 62 : Latin America Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel
- Figure 63 : Middle East & Africa Parkinson's Disease Therapeutics Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
- Figure 64 : Middle East & Africa Parkinson's Disease Therapeutics Market Value Share Analysis (US$ Mn), by Country, 2016 and 2025
- Figure 65 : Middle East & Africa Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Country, 2017–2025
- Figure 66 : Middle East & Africa Parkinson's Disease Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2025
- Figure 67 : Middle East & Africa Parkinson's Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2016 and 2025
- Figure 68 : Middle East & Africa Parkinson's Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2016 and 2025
- Figure 69 : Middle East & Africa Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Drug Class
- Figure 70 : Middle East & Africa Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Route of Administration
- Figure 71 : Middle East & Africa Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel
- Figure 72 : Global Parkinson’s Disease Therapeutics Market Share Analysis, by Company (2016)
- Figure 73 : AbbVie, Inc.’s Breakdown of Net Sales, by Region
- Figure 74 : AbbVie, Inc.’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
- Figure 75 : AbbVie, Inc.’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
- Figure 76 : UCB Inc.’s Breakdown of Net Sales, by Region
- Figure 77 : UCB Inc.’s Breakdown of Net Sales, by Therapeutic Area
- Figure 78 : UCB Inc.’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
- Figure 79 : UCB Inc.’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
- Figure 79 : UCB Inc.’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
- Figure 80 : Merck & Co., Inc.’s Sales Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
- Figure 81 : Merck & Co., Inc.’s Net Sales Breakdown, by Region, 2016
- Figure 82 : Merck & Co., Inc.’s Breakdown of Net Sales, by Business Segment, 2016
- Figure 83 : Merck & Co., Inc.’s Research and Development Expenditure (US$ Mn) and Intensity (%), 2016 and 2015
- Figure 84 : Valeant Pharmaceuticals International, Inc.’s Breakdown of Net Sales, by Region, 2016
- Figure 85 : Valeant Pharmaceuticals International, Inc.’s Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2016
- Figure 86 : Valeant Pharmaceuticals International, Inc.’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
- Figure 87 : Novartis AG’s Breakdown of Net Sales, by Region
- Figure 88 : Novartis AG’s Breakdown of Net Sales, by Business Segment
- Figure 89 : Novartis AG’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2015–2016
- Figure 90 : Novartis AG’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
- Figure 91 : Boehringer Ingelheim GmbH Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
- Figure 92 : Boehringer Ingelheim GmbH’s Breakdown of Net Sales, by Business and Business Segment Level, 2016
- Figure 93 : Boehringer Ingelheim GmbH’s Breakdown of Net Sales, by Region (Company Level), 2016
- Figure 94 : Boehringer Ingelheim GmbH’s R&D Expenditure (US$ Bn), 2013–2016
- Figure 95 : GSK’s Sales Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2016
- Figure 96 : GSK’s Breakdown of GSK’s Pharmaceutical’s R&D Expenditure (US$ Bn)
- Figure 97 : GSK’s Breakdown of GSK’s Net Sales, by Region, 2016
- Figure 98 : GSK’s Breakdown of GSK’s Net Sales, by Business Segment, 2016
- Figure 99 : Teva Pharmaceutical Industries Ltd.’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
- Figure 100 : Teva Pharmaceutical Industries Ltd.’s R&D Intensity and Sales & Marketing Intensity (%) – Company Level, 2015–2016
- Figure 101 : Teva Pharmaceutical Industries Ltd.’s Breakdown of Net Sales, by Region 2016
- Figure 102 : Teva Pharmaceutical Industries Ltd.’s Breakdown of Net Sales, (Overall Company Level), 2016
- Figure 103 : STADA’s Breakdown of Net Sales, by Region, 2016
- Figure 104 : STADA’s Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2016
- Figure 105 : STADA’s Breakdown of Net Sales, by Business Segment Level, 2016
- Figure 106 : Impax’s Breakdown of Net Sales, by Region, 2016
- Figure 107 : Impax’s Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2016
- Figure 108 : Impax’s Breakdown of Net Sales, by Business Segment Level, 2016
- Figure 109 : F. Hoffmann-La Roche AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
- Figure 110 : F. Hoffmann-La Roche AG Marketing and R&D Expenses, 2015–2016
- Figure 111 : F. Hoffmann-La Roche AG Breakdown of Net Sales, by Business Division, 2016
- Figure 112 : F. Hoffmann-La Roche AG Breakdown of Net Sales (Pharmaceutical Segment), by Region, 2016
Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.